10 Best Performing Pharma Stocks So Far in 2025

3. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

YTD Performance: 50%

Number of Hedge Fund Holders: 16

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is an emerging clinical-stage biotech firm that uses AI, bioinformatics, experimental biology, and automation to industrialize drug discovery for various diseases. It also collaborates with leaders in the drug discovery space to reduce timelines and costs for identifying and optimizing lead candidates.

The company’s Recursion Operating System (OS), a platform built across diverse technologies, allows it to map and navigate trillions of chemical and biological relationships within the Recursion Data Universe. It has several clinical programs, including REC-994, REC-2282, REC-4881 and REC-3964.

Investors are bullish on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) as Nvidia Corp. held on to its shares in the company while disposing of stocks in other companies. Nvidia Corp recently submitted regulatory filings showing ownership reduction and increases in various stocks, retaining its 7.7-million holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). This news instilled optimistic sentiments in the company’s future performance. The company ranks third on our list of the 10 best performing pharma stocks so far in 2024.